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I-124 Imaging and Dosimetry
I-124 Görüntüleme ve Dozimetri
Abstract
Although radioactive iodine imaging and therapy are one of the earliest applications of theranostics, there still remain a 
number of unresolved clinical questions as to the optimization of diagnostic techniques and dosimetry protocols. I-124 as 
a positron emission tomography (PET) radiotracer has the potential to improve the current clinical practice in the diagnosis 
and treatment of differentiated thyroid cancer. The higher sensitivity and spatial resolution of PET/computed tomography 
(CT) compared to standard gamma scintigraphy can aid in the detection of recurrent or metastatic disease and provide more 
accurate measurements of metabolic tumor volumes. However the complex decay schema of I-124 poses challenges to 
quantitative PET imaging. More prospective studies are needed to define optimal dosimetry protocols and to improve patient-
specific treatment planning strategies, taking into account not only the absorbed dose to tumors but also methods to avoid 
toxicity to normal organs. A historical perspective of I-124 imaging and dosimetry as well as future concepts are discussed.
Keywords: I-124 positron emission tomography/computed tomography, dosimetry, thyroid cancer
Öz
Radyoaktif iyot görüntüleme ve tedavisi teranostiğin ilk uygulamalarından biri olmasına rağmen, halen tanı teknikleri ve 
dozimetri protokollerinin optimizasyonu ile ilgili çözümlenmemiş klinik sorular bulunmaktadır. Pozitron emisyon tomografi 
(PET) radyofarmasötiği olarak I-124, mevcut klinik uygulamada diferansiye tiroid kanserlerinin tanı ve tedavisini geliştirme 
potansiyeline sahiptir. Standart gamma sintigrafisi ile karşılaştırıldığında PET/bilgisayarlı tomografinin yüksek duyarlılık ve 
uzaysal çözünürlüğü nüks veya metastatik hastalığın saptanmasında yardımcı olabilir ve metabolik tümör hacimlerinin daha 
doğru ölçülmesini sağlayabilir. I-124’ün karmaşık bozunma süreci kantitatif PET görüntüleme için zorluklar teşkil etmektedir. 
Optimum dozimetre protokollerini tanımlamak ve hastaya özgü tedavi planlama stratejilerini sadece tümör tarafından abzorbe 
edilen doza değil normal organlara toksisiteyi önleyecek metotlara dayanarak iyileştirecek prospektif çalışmalara ihtiyaç vardır. 
I-124 görüntüleme ve doz ölçümünün tarihsel perspektifi ile gelecekteki kavramlar tartışılmıştır.
Anahtar kelimeler: I-124 pozitron emisyon tomografi/bilgisayarlı tomografi, dozimetri, tiroid kanseri
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Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.
67
Kuker et al. I-124 Imaging and DosimetryMol Imaging Radionucl Ther 2017;26(Suppl 1):66-73
Introduction
The mainstay of current clinical radioactive iodine (RAI) 
imaging and dosimetry utilizes the radioisotope I-131. The 
physical half life of I-131 is 8.02 days that allows imaging 
and data acquisition at sequential time points over a 
period of several days. The high energy gamma emissions 
of 364 keV, however, are a drawback due to poor image 
quality resulting in less than optimal evaluation of extent 
of disease and quantitation. Another factor contributing 
to poor image quality is the relatively small administered 
activities in the range of 2-5 mCi. The clinical safety/
efficacy of higher administered activities of I-131 has been 
questioned due to concern for the “stunning effect” when 
it is used prior to RAI treatment. I-131 remains the standard 
treatment for differentiated thyroid cancer (DTC) because 
of its beta emissions with a maximum energy of 606 keV 
and tissue penetration of 0.6-2 mm.
I-123 is predominantly a gamma emitter with an energy 
of 159 keV, which is near the optimal range for standard 
gamma camera imaging. In addition, higher administered 
activities can be used as compared to I-131 because of less 
concern for stunning. Although the physical properties of 
I-123 contribute to improved image quality, there are also 
several drawbacks. I-123 is is more expensive and is not as 
widely available as I-131. The absence of beta decay does 
not permit the use of I-123 for therapeutic applications, 
and the relatively short half life of 13 hours limits its utility 
for dosimetry protocols.
I-124 is a PET radiopharmaceutical with a 4.2-day half life. 
It offers superior imaging characteristics with enhanced 
spatial resolution and image sensitivity due to coincidence 
detection on PET cameras. I-124 also has a favorable half 
life that permits the evaluation of in-vivo iodine kinetics. 
However, I-124 has a rather complex decay schema, which 
creates challenges in optimal imaging. There exist a number 
of reports attesting the potential clinical benefits of I-124 
imaging in patients with DTC, however, a uniform clinical 
protocol for imaging, image analysis and quantitation has 
not yet been firmly established. 
History of I-124 in Clinical Practice
The use of I-124 in clinical practice in a patient with DTC was 
first described in 1960 (1), and the first PET-based dosimetry 
study based on serial measurements in DTC patients was 
published in 1999 (2) after phantom studies demonstrated 
that quantification was feasible (3). Since then, there have 
been several key articles demonstrating the clinical utility of 
I-124 and its role in the detection of residual thyroid tissue 
and/or metastasis in patients with DTC (4,5,6,7,8); and the 
following are some more recent highlights.
In 2010, Van Nostrand et al. (6) compared the ability of 
I-124 PET versus I-131 planar whole body imaging in 
detecting residual thyroid tissue and/or metastatic DTC. 
Twenty-five patients were included in the study. Eight of 
the 25 patients showed more positive foci of uptake on 
I-124 images than on I-131. I-124 demonstrated the same 
number of foci as on I-131 in 16 patients. One patient had 
one additional positive focus on I-131 not seen on I-124, 
which could not be confirmed as a metastasis. Out of 97 
positive foci, I-124 identified 49 that were not seen with 
I-131, and I-131 identified one positive focus not seen with 
I-124. They concluded that relative to I-131 planar whole 
body imaging, I-124 PET identified as many as 50% more 
foci of radioiodine uptake suggestive of residual thyroid 
tissue and/or metastases in as many as 32% more patients 
who had DTC.
In 2015, as part of the THYROPET study, Kist et al. (7) 
focused on a subset of patients with suspected recurrence 
from DTC, based on an increased thyroglobulin level and 
negative neck ultrasound. All patients underwent I-124 
PET/CT after rhTSH stimulation. Subsequently, after 4-6 
weeks of thyroid hormone withdrawal, the patients were 
treated with 150-200 mCi of I-131 and underwent a planar 
whole body scan (WBS) one week later. The study was 
terminated preliminarily after inclusion of 17 patients. 
Eight post-therapy WBS were negative (47%), all of which 
were correctly predicted by a negative I-124 PET/CT. Nine 
post-therapy WBS showed RAI avid tumor, of which only 
four also had positive I-124 PET/CT findings. The authors 
observed that 29% of patients (5/17) would have been 
denied potentially effective RAI therapy if I-124 PET/
CT was implemented. Of the false negative lesions with 
anatomical correlates on CT, the majority were located in 
the lungs. They concluded that the high false negative rate 
of rhTSH stimulated I-124 PET/CT precludes its use as a 
scouting procedure in this cohort of patients. The authors 
postulate that their observed false negative rate may have 
been influenced by the 2 mCi dose of I-124 as compared to 
the higher doses of I-131 and the use of rhTSH instead of 
thyroid hormone withdrawal.
In 2016, our group conducted a phase I/II study to 
determine the imaging characteristics and clinical feasibility 
of I-124 PET/CT for the determination of disease extent and 
evaluation of RAI kinetics in its physiologic and neoplastic 
distribution in patients with DTC (8). Fifteen patients were 
included in the study. All patients who had I-124 imaging 
subsequently underwent RAI treatment with administered 
activities of I-131 in the range of 100 to 300 mCi. Post-
treatment planar whole body and static images were 
obtained 5 to 7 days after RAI treatment and used as a 
reference to compare with the pre-treatment I-124 PET/
CT scans. Forty-six distinct lesions were identified in these 
15 patients on I-124 PET/CT images with a sensitivity of 
92.5%. I-124 identified 22.5% more foci of RAI avid lesions 
as compared to the planar I-131 post-treatment scans. In 
addition, the I-124 images provided discriminating details 
in terms of location and laterality of remnant thyroid 
tissue even when no remnant tissue was appreciated on 
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anatomical imaging. Our group concluded that I-124 PET/
CT is a valuable clinical imaging tool/agent, in both extent 
of disease evaluation in the setting of metastatic DTC and 
the functional volumetric and kinetic evaluation of target 
lesions.
I-124 Properties and Decay Schema
I-124 is cyclotron produced and because of its 4.2-day half 
life can be easily transported for clinical use. I-124 has a 
positron abundance (number of positrons emitted per decay) 
of only 23% with maximum and mean positron energies 
of 2138 and 819 keV, respectively. In contrast, the most 
common PET radiotracer, F-18, has a positron abundance of 
97% with maximum and mean positron energies of 634 and 
250 keV, respectively. It is estimated that this high positron 
emission energy results in a spatial resolution loss of about 
1 mm compared to F-18 FDG which has a spatial resolution 
on the order of 5-10 mm depending on the scanner and 
clinical reconstruction parameters (3). 
In addition to positron emissions, I-124 emits a rather large 
portion of gamma rays during its decay, over half of which 
have an energy of 603 keV (Table 1). Coincidences of this 
604 keV photon and a 511 keV annihilation photon cannot 
be distinguished from the true coincidences involving two 
511 keV annihilation photons. These gamma coincidences 
result in background activity on the PET images which has 
also been described for other PET radiotracers with longer 
half lives such as Y-86 and Br-76 (9,10). Multiple correction 
methods have been suggested to address this background 
activity but their effectiveness is limited in the setting of 
the low count rates observed on clinical I-124 scans. In 
addition, the large amount of gamma emissions leads to 
higher random coincidence rates, increased dead time and 
inaccurate dead time correction (10). Improved gamma 
coincidence correction and dead time correction methods 
are necessary to ensure accurate quantitative imaging of 
I-124 (11).
Background of Radioactive Iodine Dosimetry
The general principle of RAI dosimetry relies on the premise 
that administered activities for diagnostic or therapeutic 
purposes should be as low as reasonably achievable to 
limit the radiation burden to the individual as well as the 
general population. RAI treatment is one of the earliest 
applications of theranostics and is certainly a strong 
therapeutic intervention, along with surgical treatment, in 
the management of DTC. The term “ablation” is used when 
RAI is given to destroy residual thyroid tissue in the absence 
of functioning thyroid cancer. The term “therapy” refers to 
administration of RAI for residual, recurrent or metastatic 
DTC. Although RAI therapy is generally well tolerated, 
serious side effects can occur and may be deterministic 
Table 1. I-124 simplified decay schema and main emissions
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(severity increases with dose and threshold dependent) or 
stochastic (occur by chance and non-threshold dependent). 
Deterministic effects of RAI therapy can be early and 
usually transient (i.e. gastritis, sialadenitis, hypospermia or 
amenorrhea) or late (i.e. sicca syndrome, lung fibrosis or 
bone marrow depression). Secondary malignancy is the 
main stochastic effect of RAI therapy although the incidence 
is relatively low and comparable to other modalities such as 
external radiotherapy.
The activity to be used for RAI therapy remains a subject of 
discussion. Although an empiric fixed-dose RAI treatment 
protocol is still in common use, the therapeutic profile of 
RAI is best achieved by application of dosimetry-guided, 
patient-specific treatment planning. Two approaches for 
RAI dosimetry have been applied in clinical practice: the 
maximum safe dose approach which was first introduced 
by Benua and Leeper and is aimed at administering the 
highest amount of I-131 which does not result in bone 
marrow suppression (<2 Gy absorbed dose to the bone 
marrow with a whole body retention <4.44 GBq at 48 
hours) (12,13) and the lesion-based dosimetry method 
based on the data by Maxon et al. (14,15) in which a 
target dose (at least 80 Gy to metastatic sites and 300 Gy 
to thyroid remnants) is calculated on the basis of planar 
diagnostic I-131 scanning. 
The maximum safe dose approach focuses on the safety 
of RAI treatment. Blood is used as a surrogate of the red 
bone marrow, which is considered as the critical organ in 
this approach. Over the years, the original Benua method 
was refined with improved patient specificity using Medical 
Internal Radiation Dose (MIRD) methodology. Strengths of 
the blood-based dosimetry approach include determination 
of the maximum safe activity of RAI for each individual 
patient, identification of patients for whom empiric fixed 
activities are not considered safe, and the potential to 
administer higher activities at once instead of multiple 
fractions of lower activity in order to avoid changes in 
tumor/lesion biokinetics. Although there is a long history of 
using this treatment strategy at multiple institutions, there 
is a paucity of clinical data to show improved response or 
outcome rates. In addition, the absorbed dose to the tumor 
is not known in this approach and although controversial, 
there is a risk of stunning with dosimetric administrations 
of I-131 that may alter tumor/lesion biokinetics during 
subsequent treatment (16).
The objective of lesion-based dosimetry is to determine 
the RAI activity that delivers the recommended absorbed 
dose of radiation to ablate thyroid remnants or treat 
metastatic disease while minimizing the risk to patients. 
The calculation of lesion dose is generally based on MIRD 
methodology and for smaller lesions the spherical model of 
OLINDA/EXM can be employed. In lesion-based dosimetry, 
not only is it important to determine how much activity 
is contained within the lesion, it is also necessary to 
calculate the mass of the lesion. This can be challenging 
especially for ablation purposes as measuring the size of 
thyroid remnants is often not reliable using anatomical 
imaging such as ultrasound or computed tomography 
(CT). Some disadvantages of a lesion-based approach to 
RAI treatment include the wide range of absorbed doses 
to lesions within a given patient and the inhomogeneous 
absorbed dose distributions and lack of accurate models to 
reflect RAI kinetics within individual lesions (16). Since the 
accuracy of all dosimetric approaches relies on the accurate 
quantitation of RAI kinetics, I-124 being a PET radiotracer 
with enhanced spatial resolution may play a pivotal role in 
this area.
I-124 Dosimetry Protocols and Clinical Applications
Why is I-124 well-suited for RAI dosimetry? Of the available 
radio-iodine isotopes, I-123 would be the preferred agent 
for dosimetry given its photopeak that is close to the 
optimal range for gamma camera imaging; however, its 
relatively short half life precludes imaging at sequential time 
points in a practical manner. I-131 is relatively inexpensive, 
is widely available and has become the mainstay of RAI 
dosimetry. However, only small administered activities 
can be given because of the risk of stunning. Additionally 
the high energy gamma emissions result in poor image 
quality. I-124 behaves biochemically similar to I-131 and its 
physical half life of 4.2-days makes it suitable for sequential 
time point imaging and absorbed dose calculations. With 
I-131 planar imaging, there is uncertainty regarding RAI 
avid lesion dimensions, and with single-photon emission 
computed tomography (SPECT), the counting rate at 
diagnostic activity levels is inadequate for accurate 
quantification. Given the added benefit of PET/CT with 
I-124, not only can fine details be discriminated that are 
not visible on low-dose planar imaging but also areas of 
radiotracer uptake can be detected that do not have a 
measurable anatomical correlation on CT (such as with 
thyroid remnants as observed in our study). However, there 
are drawbacks of using I-124 for RAI dosimetry including 
its relatively high cost and complex decay schema, which 
may lead to background noise and voxel oversaturation 
even at low administered activities.
Several investigational studies have successfully used I-124 
PET alone and with CT to guide postsurgical treatment and, 
in particular, RAI therapy in patients with DTC. The number 
of measurement time points varies for each I-124 dosimetry 
protocol described in the literature (17,18,19,20,21,22,23). 
An important observation that should be highlighted is the 
high intra- and inter-lesional variability in RAI avid tumors 
(18) as well as in normal tissues such as salivary glands 
(24,25). 
Our group demonstrated different kinetic profiles for 
normal thyroid remnants, salivary glands, and metastatic 
lesions as well as individual variations in functional 
volumes, and thus cumulated activities (8). The sequential 
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I-124 PET/CT images consistently demonstrated the 
maximum activity within thyroid remnant tissue to 
occur at 24 hours. After the peak activity was reached, 
the clearance was mono-exponential. The maximum 
remnant activity ranged from 0.044 to 7.988 MBq with 
the total functional remnant volume (the total number 
of voxels within the remnant ROI) ranging from 1 to 60 
ml. Physiologic activity within the salivary glands reached 
a peak at 4 hours after radioiodine administration. The 
salivary gland clearance was bi-exponential with an 
average of 81% of the activity being cleared from the 
salivary glands by 24 hours. In contrast, metastatic disease 
to lymph nodes demonstrated an uptake pattern that 
was significantly different than the thyroid remnant or 
physiologic salivary gland activity. A progressive increase 
in activity with protracted retention was identified as 
a characteristic pattern for metastatic nodal disease. 
The remnant data is particularly interesting as it again 
highlights the potential value of individualized patient-
specific dosimetric assessment even for purposes of 
thyroid remnant ablation rather than an empiric or “one 
dose fits all” approach. However, a larger scale remnant 
dosimetry study is required to address this issue.
Why do we need RAI dosimetry? Although many centers 
have adapted a fixed-dose of I-131 in the range of 100-
200 mCi for the treatment of metastatic DTC, there are 
several drawbacks to using this empiric technique. Without 
knowledge of the rate of radiobiological clearance as well 
as the degree of intra-lesion variability in absorbed dose, 
a proportion of patients will be over- or under-treated 
using an empiric dose of I-131. Benua et al. (12) observed 
that repeated sub-therapeutic doses of RAI might induce 
dedifferentiation and loss of iodine-concentrating ability of 
tumors. The rationale of using the highest possible dose 
is based on the radiobiologic fact that radiation treatment 
efficacy is directly related to the radiation dose delivered. 
Therefore, the goal of dosimetry-guided RAI therapy is to 
derive a patient-specific dose that will deliver the highest 
possible tumoricidal effect to metastatic sites while 
minimizing toxicity to normal tissues. Another potential 
application of RAI dosimetry involves the ablation of thyroid 
remnants where the goal is to deliver the lowest possible 
ablative dose taking into account patient-specific factors 
such as the functional volume of thyroid tissue remaining 
as well as the variability in dose distribution.
Technical Considerations of I-124 Dosimetry
Traditional I-131 dosimetry using MIRD methodology 
involves sequential time point whole body imaging and 
blood sampling to obtain time activity curves and residence 
times for the whole body and bone marrow compartments. 
The classic formula D= xS, takes into account the cumulated 
activities derived from both compartments incorporating 
gamma emissions from the whole body to the bone marrow 
and beta emissions from the bone marrow to the bone 
marrow. The S values are obtained from anthropomorphic 
phantoms and assume uniform distribution of activity 
within a source organ of defined geometry. 
Our group applied the MIRD schema to define a protocol 
for I-124 dosimetry. The protocol involves acquiring whole 
body PET/CT images and blood samples at 4 different 
time points, i.e. 4, 24, 48 and 72 hours following the 
administration of a 2 mCi dose of I-124. Regions of interest 
were drawn around the whole body at each time point in 
order to generate a time activity curve for the whole body 
compartment. Similarly, I-124 counts were measured from 
the blood samples at each sequential time point to generate 
a time activity curve for the bone marrow compartment 
(assuming a uniform distribution of blood within the bone 
marrow). Cumulated activities and residence times for the 
whole body and bone marrow compartments were then 
obtained by calculating the area under each respective 
time activity curve. The target organ in this case is the bone 
marrow since the goal of dosimetry-guided RAI treatment 
is to deliver the maximum permissible dose to the patient 
without permanent damage to the bone marrow. The 
source organs are the whole primarily (primary in the form 
of gamma emissions) and the bone marrow (primarily in 
the form of beta emissions). The absorbed dose to the 
target organ is the sum of the cumulated activities from 
the source organs multiplied by their respective S values.
What are some drawbacks of this method? One drawback 
of the traditional MIRD schema is that the absorbed dose 
to the tumor is not routinely calculated. Given the wide 
range of dose variability within a tumor, one cannot be 
confident (based on bone marrow dosimetry alone) that a 
lesion will receive a sufficient dose to produce the desired 
tumoricidal effect. Another limitation revolves around the 
use of the S values which are derived from anthropomorphic 
phantoms with uniform activity distribution and defined 
geometry. Although this is generally acceptable for bone 
marrow dosimetry (with only two source organs), it is not 
applicable for lesion-based dosimetry where commonly 
lesions are encountered with complex shapes and non-
uniform distributions of activity. A distinct advantage 
of I-124 dosimetry lies in its application for lesion-based 
dosimetry where the higher resolution PET/CT images 
allow for improved lesion contouring and quantification. 
Our group demonstrated that there is a significant variation 
in cumulated activities within individual lesions, whether 
the lesions depict normal physiologic uptake (as in the 
salivary glands or thyroid remnants) versus metastatic foci 
(8). These variations in cumulated activities clearly alter 
the dosimetric input and cannot be distinguished using 
traditional I-131 techniques.
For complex lesions which cannot be evaluated using 
standard anthropomorphic phantoms, voxel-based can be 
employed, which utilizes or not Monte Carlo based codes. 
In the simplest voxel-based dosimetry, a lesion (whether it 
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be normal tissue, an individual tumor or a region within 
a tumor) is divided into voxels of the same 3-dimensional 
geometry. MIRD formalism is then applied so that the 
cumulated activity is calculated for each individual voxel 
comprising the lesion. Each voxel has an assigned S value 
based on the radioisotope and its location within the lesion, 
which is assumed to be a homogeneous tissue medium. 
The absorbed dose to a target lesion is then calculated by 
summing the products of the cumulated activities and S 
values of the individual source voxels in a 3-dimensional 
array (34). The S values are precalculated standarized 
parameters which do not consider patient-specific tissue 
heterogeneities. In this case they represent point-dose or 
voxel-dose kernels. They can be calculated through MC 
methods (in this case the dosimetry might be considered 
a type of MC based dosimetry) or through deterministic 
ones.
MC transport codes can take lesion-based dosimetry to 
another level by addressing tissue inhomogeneity and 
assessing their influence on the resulting dose distributions. 
Target lesions are again divided into iso-volumetric voxels 
and the cumulated activities are calculated for each 
individual voxel. However, instead of utilizing S values 
kernels from standarized uniform tissues, MC based fully 
developed dosimetries utilize a more complex approach. 
MC codes can incorporate the probabilistic interactions of 
radiation with matter including multiple different particles 
(beta, gamma, photoelectric absorption, Compton scatter 
and electron-positron pair production) contributing to the 
absorbed target dose from multiple different pathways that 
are modeled by computer program computations. MC codes 
together with appropriate physical data and modeling can 
provide the most realistic numerical evaluations. Amongst 
the most evolved, complete and reliable codes of this type 
are MCNP6 (26), GEANT4 (27,28), and FLUKA (29,30).
Future I-124 Dosimetry Concepts
Areas of future investigation for I-124 dosimetry involve 
issues related to data collection and data processing. It is 
widely accepted that 4 time points are required for accurate 
curve fitting models in order to calculate the cumulated 
activity. Can this method be streamlined so that fewer time 
points are needed to generate similar time activity curves 
with minimal effect on the cumulated activity? This may be 
plausible given the shorter half life of I-124 as compared 
to I-131. Another area that our group is focusing on 
involves the identification of a surrogate for bone marrow 
activity on anatomical imaging rather than relying on blood 
sampling. Can a region of interest be drawn on PET/CT 
(for example around the aorta, vertebral bodies or soft 
tissues) to simulate the activity within the bone marrow 
compartment? Our preliminary data indicates that this is 
likely feasible but a larger patient population is needed for 
statistical power.
Applying MC codes in I-124 dosimetry is another area 
of future investigation. MC codes for particle transport 
pursue the calculation of the random walk, or the track, 
of (numerical) particles analogous to what would occur 
in reality. I-124 imaging intrinsically gives information of 
iodine position and concentration and, therefore, can be 
used as a surrogate for other iodine isotopes if isotopical 
correlation and decay correction coefficients are known. 
Consequently, having iodine distribution defined from I-124 
imaging, one can feed the model with decay information of 
I-124 as well as from other iodine isotopes (considering the 
mentioned corrections) and obtain dose distributions for 
isotopes such as I-131.
The combination of MC codes and data from I-124 PET/
CT studies can help develop patient- and compound-
specific numerical models for 3D dosimetry evaluations 
(31,32). This type of dosimetry can involve triple voxelized 
models with resolutions as good as imaging studies allow: 
voxelized geometry utilizing CT data, voxelized emission 
distribution utilizing PET data, and voxelized distributions of 
dose estimators. This means that one can reach optimized 
resolutions in three aspects: geometry of the regions of 
interest, source distribution, and detection.
Utilizing this modality, one can assess more realistic particle 
transport and more representative dose values for large 
and small regions. The voxelized dose estimators are an 
important tool for defining hot and cold spots and they 
provide data for construction of dose-volume histograms 
or other dosimetry analysis tools. A great advantage of this 
modality is that it allows for accurate estimation of volume-
representative dose values. This means one can determine 
the volume of influence of a certain dose. For example, 
if bone marrow is considered, one can determine the 
maximum, mean, and minimum dose and what fraction of 
the marrow would receive more than the tolerance dose.
Great contrast appears if this dosimetry modality is compared 
to previous methods such as those based on the utilization of 
generic numerical phantoms, e.g. OLINDA/EXM (33), where 
geometry is not patient specific, organs are considered 
uniform, emitters are assumed homogeneously distributed 
in tissues, and doses are whole organ averages. This is also 
in contrast with more recent modalities based on patient-
specific PET/CT images that do not perform the particle 
transport for each case but utilize standardized fixed point-
dose kernels, voxel-dose kernels or other approximations 
(34). In some cases, the differences are not important but, 
when heterogeneities are present, large differences might 
appear. This can be the case for regions with tissue changes 
or with large activity gradients such as in thyroid remnants.
Conclusions
There are a number of ways in which I-124 PET/CT may 
contribute to current clinical practice in the management of 
patients with DTC. Studies have shown that I-124 PET/CT is 
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a superior imaging agent as compared to diagnostic I-131 
planar whole body scintigraphy with lesion detectability 
similar to post-treatment I-131 scans. In addition, the 
potential applications of quantitative I-124 PET/CT imaging 
for RAI treatment planning have been described that show 
similar benefits over traditional I-131 dosimetry techniques. 
However, due to the physical properties of I-124 and its 
complex decay schema, there remains a need for improved 
correction methods to ensure the accuracy of diagnostic 
images and quantitative analysis. Also, there is a need for 
larger prospective trials to address the number and timing 
of scans needed for optimal dosimetry protocols. Despite its 
benefits in lesion detection and measurement of metabolic 
tumor volumes, for I-124 to be used mainstream, it needs 
to be more commercially available and at a lower cost.
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